← Back to Search

LPS for Alzheimer's Disease

Phase < 1
Waitlist Available
Led By Adam Mecca, M.D., Ph.D.
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 180 minutes post intervention
Awards & highlights

Summary

This trial looks at how well microglia cells work in people with Alzheimer's Disease compared to people with no cognitive problems and to younger people.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~180 minutes post intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and 180 minutes post intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Microglial Activation Reserve Index (MARI)
Secondary outcome measures
Effects of MARI on Cognition

Side effects data

From 2016 Phase 4 trial • 16 Patients • NCT02875028
53%
headache
27%
Chills
13%
Myalgia
13%
malaise
7%
Dizziness
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Vorapaxar

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients receiving endotoxinExperimental Treatment1 Intervention
The 20 enrolled subjects will have LPS (0.4 ng/kg) administered intravenously
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LPS
2018
Completed Phase 4
~230

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,874 Previous Clinical Trials
2,953,538 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,704 Previous Clinical Trials
28,033,239 Total Patients Enrolled
Adam Mecca, M.D., Ph.D.Principal InvestigatorYale University
~3 spots leftby Jul 2025